Head-to-head · free

The Precision Peptide Company vs Sky

PNGAF vs SKY — return on capital, cash generation, margins and balance sheet side by side.

PNGAF

0 / 0

measures where PNGAF leads

SKY

0 / 0

measures where SKY leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasurePNGAFSKY · FY2026
Revenue—$2.7B
Net income—$206.9M
Revenue growth (yearly, multi-year)—4.8%
Free cash flow—$269.7M
Free cash flow margin—10.1%
Net cash / (debt)——
ROIC—11.5%
Return on equity—13.3%
Gross margin—26.4%
Operating margin—9.5%
Net debt / EBITDA—-1.74x

Figures are as reported by each company; latest fiscal year shown.

Where The Precision Peptide Company's cash went

Not reported yet.

Full PNGAF profile →

Where Sky's cash went (FY2026)

Capital spending
$34.1M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full SKY profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons